JP6125542B2 - 低血糖スルホンアミドの液体製剤 - Google Patents
低血糖スルホンアミドの液体製剤 Download PDFInfo
- Publication number
- JP6125542B2 JP6125542B2 JP2014559281A JP2014559281A JP6125542B2 JP 6125542 B2 JP6125542 B2 JP 6125542B2 JP 2014559281 A JP2014559281 A JP 2014559281A JP 2014559281 A JP2014559281 A JP 2014559281A JP 6125542 B2 JP6125542 B2 JP 6125542B2
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- diabetes
- formulation according
- sodium
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000007788 liquid Substances 0.000 title claims description 11
- 229940124530 sulfonamide Drugs 0.000 title description 34
- 150000003456 sulfonamides Chemical class 0.000 title description 34
- 230000002218 hypoglycaemic effect Effects 0.000 title description 32
- 239000000203 mixture Substances 0.000 claims description 148
- 238000009472 formulation Methods 0.000 claims description 143
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 41
- 229960004580 glibenclamide Drugs 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 33
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000002562 thickening agent Substances 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 22
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 22
- 239000007853 buffer solution Substances 0.000 claims description 21
- 239000011734 sodium Substances 0.000 claims description 21
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 20
- 239000003755 preservative agent Substances 0.000 claims description 20
- 229920001285 xanthan gum Polymers 0.000 claims description 20
- 239000000230 xanthan gum Substances 0.000 claims description 20
- 235000010493 xanthan gum Nutrition 0.000 claims description 20
- 229940082509 xanthan gum Drugs 0.000 claims description 20
- 239000001509 sodium citrate Substances 0.000 claims description 18
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 208000029140 neonatal diabetes Diseases 0.000 claims description 17
- 230000002335 preservative effect Effects 0.000 claims description 17
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 15
- 239000004299 sodium benzoate Substances 0.000 claims description 15
- 235000010234 sodium benzoate Nutrition 0.000 claims description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 8
- 230000001052 transient effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 208000019505 Deglutition disease Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 230000009456 molecular mechanism Effects 0.000 claims description 6
- 230000003557 neuropsychological effect Effects 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 206010011878 Deafness Diseases 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 230000010370 hearing loss Effects 0.000 claims description 4
- 231100000888 hearing loss Toxicity 0.000 claims description 4
- 208000016354 hearing loss disease Diseases 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 3
- 230000002028 premature Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229920002125 Sokalan® Polymers 0.000 description 14
- 229940083542 sodium Drugs 0.000 description 13
- 229920002678 cellulose Chemical class 0.000 description 10
- 239000001913 cellulose Chemical class 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 239000001632 sodium acetate Substances 0.000 description 8
- 235000017281 sodium acetate Nutrition 0.000 description 8
- 229960001466 acetohexamide Drugs 0.000 description 7
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 7
- 229960004346 glimepiride Drugs 0.000 description 7
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 206010036590 Premature baby Diseases 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- -1 glyquidone Chemical compound 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 159000000001 potassium salts Chemical class 0.000 description 6
- 229960003362 carbutamide Drugs 0.000 description 5
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 4
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 4
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 229960001761 chlorpropamide Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 231100000063 excitotoxicity Toxicity 0.000 description 4
- 229960001764 glibornuride Drugs 0.000 description 4
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 4
- 229960000346 gliclazide Drugs 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229950002888 glyclopyramide Drugs 0.000 description 4
- 229960005125 metahexamide Drugs 0.000 description 4
- XXYTXQGCRQLRHA-UHFFFAOYSA-N metahexamide Chemical compound C1=C(N)C(C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 XXYTXQGCRQLRHA-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- AFOGBLYPWJJVAL-UHFFFAOYSA-N phenbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=CC=C1 AFOGBLYPWJJVAL-UHFFFAOYSA-N 0.000 description 4
- 229950008557 phenbutamide Drugs 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000004334 sorbic acid Substances 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 229940075582 sorbic acid Drugs 0.000 description 4
- 229960002277 tolazamide Drugs 0.000 description 4
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 4
- 229960005371 tolbutamide Drugs 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002730 mercury Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 208000032253 retinal ischemia Diseases 0.000 description 3
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 3
- 239000004324 sodium propionate Substances 0.000 description 3
- 235000010334 sodium propionate Nutrition 0.000 description 3
- 229960003212 sodium propionate Drugs 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000760570 Homo sapiens ATP-binding cassette sub-family C member 8 Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 240000004584 Tamarindus indica Species 0.000 description 2
- 235000004298 Tamarindus indica Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000001761 ethyl methyl cellulose Substances 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 229960003236 glisoxepide Drugs 0.000 description 2
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229960004906 thiomersal Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100024645 ATP-binding cassette sub-family C member 8 Human genes 0.000 description 1
- 102100021177 ATP-sensitive inward rectifier potassium channel 11 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 208000006597 Choroid Hemorrhage Diseases 0.000 description 1
- 206010008786 Choroidal haemorrhage Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101000614701 Homo sapiens ATP-sensitive inward rectifier potassium channel 11 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 231100000265 Toxic optic neuropathy Toxicity 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- GHXRKGHKMRZBJH-UHFFFAOYSA-N boric acid Chemical compound OB(O)O.OB(O)O GHXRKGHKMRZBJH-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 235000021091 sugar-based sweeteners Nutrition 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
グリベンクラミド又は5−クロロ−N−[2−[4−(シクロヘキシルカルバモイルスルファモイル)フェニル]エチル]−2−メトキシベンズアミド(UIPAC命名法)は、膵臓細胞の表面上に存在するATP依存性カリウムチャネル(KATP)の阻害剤である。グルコースと同様に、それは、膵臓β細胞によるインスリンの分泌を刺激することにより作用する。この化合物は、また、名前グリブリド(USAN)により公知であり、スルホニル尿素ファミリーに属し、2型糖尿病の処置において一般に使用される。
本発明者らは、特性が、特に乳児、特に未熟児、幼い子供、又は錠剤を服用する困難を有しうる人への、経口経路による投与と、あるいは、眼経路による投与と適合する、低血糖スルホンアミドの医薬的製剤を開発している。
本発明者らは、経口経路による又は眼経路による投与のために適した液体低血糖スルホンアミド製剤を開発している。特に、本発明者らは、小児での使用における経口投与のために特に適した製剤を開発している。小児の必要性のために適した医薬的製剤は、成人のために意図された製剤について必ずしも考慮されていない特定の基準を満たす。例えば、小児用製剤は、好ましくは、液体製剤であって、許容可能な味を伴い、匂いはほとんど無いか全く無く、幼い患者の年齢、体重、及び要件に従って変動する正確な用量の投与を可能にする。低血糖スルホンアミドの経口投与のための液体製剤の開発は、それらが血糖症の障害の処置においてしばしば使用されている点、及び、それらの製剤が、好ましくは、従って、任意の糖ベースの甘味料又は甘味剤を含んでいない点で、尚更に複雑である。
− 緩衝系及び希釈剤、好ましくは水を混合すること;
− 微粒子化粒子を加え、粒子の均一な分布が得られるまで混合すること;
− 増粘剤を加え、調製物を、均一なゲルが得られるまで振盪すること;
− 調製物が、所望の粘度に達するまで静置すること許すこと;
− 必要な場合、pHを調整すること;及び
− 最終容積を、希釈剤を加えることにより調整すること。
1.低血糖スルホンアミドの微粒子化粒子を含む液体医薬的製剤であって、粒子の90%が、サイズ30μm未満、少なくとも1つの増粘剤、及び前記製剤のpHを4〜8の間で維持する緩衝系を含む。
本発明者らは、中性の味を伴い、任意の苦味を伴わない、無臭の白色の懸濁液の形態を有するグリベンクラミド製剤を開発している。この製剤は、風味又は着色を加える必要を伴わず、乳児及び幼い子供におけるその使用を想定することを許す。
成分 5mLについての単位量
グリベンクラミド 3mg
ヒドロキシエチルセルロース(Natrosol 250G Pharm) 25mg
キサンタンガム 25mg
安息香酸ナトリウム 25mg
乳酸 pH4.8にするのに十分な量
クエン酸ナトリウム 37.5mg
精製水 5mLにするのに十分な量
成分 5mLについての単位量
グリベンクラミド 30mg
ヒドロキシエチルセルロース(Natrosol 250G Pharm) 25mg
キサンタンガム 25mg
安息香酸ナトリウム 25mg
乳酸 pH4.8にするのに十分な量
クエン酸ナトリウム 37.5mg
精製水 5mLにするのに十分な量
3つの異なるグリベンクラミド製剤を、一晩の10時間の絶食後、18人の健康な成人ボランティアに経口投与した。各々のボランティアが、5mgのグリベンクラミドの単一投与を受け、平均血漿濃度を36時間にわたりモニターした。低血糖の任意のリスクを回避するため、ボランティアに、10%グルコース注入を、100mL/時間の用量で、グリベンクラミドの投与前30分、及び、その後の3.5時間にわたり与えた。
Claims (16)
- グリベンクラミドの微粉化粒子を0.1ないし10mg/mL、ヒドロキシエチルセルロースおよびキサンタンガムである増粘剤を8ないし15mg/mL、クエン酸ナトリウムおよび乳酸からなり製剤のpHを4−6に維持する緩衝系、および安息香酸またはそのナトリウムもしくはカリウム塩からなる群から選択される保存剤を0.5ないし10mg/mLからなる液体医薬製剤。
- 安息香酸ナトリウムである保存剤を含むことを特徴とする、請求項1記載の製剤。
- 微粉化粒子の少なくとも90%が、サイズ30μm未満を有することを特徴とする、請求項1または2のいずれか一項記載の製剤。
- 微粉化粒子の少なくとも90%が、サイズ10μm未満を有することを特徴とする、請求項1〜3のいずれか一項記載の製剤。
- 350〜450mPa.sの間に含まれる粘度を有することを特徴とする、請求項1〜4のいずれか一項記載の製剤。
- 浸透圧400mOsm/L未満を有することを特徴とする、請求項1〜5のいずれか一項記載の製剤。
- 0.1〜10mg/mLの間のグリベンクラミド、約5mg/mLのヒドロキシエチルセルロース、約5mg/mLのキサンタンガム、約5mg/mLの安息香酸ナトリウム、ならびに、pHを約4.8で維持する、クエン酸ナトリウム及び乳酸で構成される緩衝系を含むことを特徴とする、請求項1〜6のいずれか一項記載の製剤。
- 容積送達系を含むか、又はそれに関連付けられる容器中に、あるいは単一用量容器中にパッケージ化することを特徴とする、請求項1〜7のいずれか一項記載の製剤。
- 経口、眼、直腸、又は膣経路による投与のために意図されていることを特徴とする、請求項1〜8のいずれか一項記載の製剤。
- 経口経路による又は眼経路による投与のために意図されていることを特徴とする、請求項1〜9のいずれか一項記載の製剤。
- ヒト又は動物における、好ましくはヒトにおける疾患の処置における使用のための、請求項1〜10のいずれか一項記載の製剤。
- ヒトが、乳児、幼い子供、嚥下障害に苦しんでいる人、及び高齢の人からなる群において選択されることを特徴とする、請求項11記載の製剤。
- 乳児が未熟児であることを特徴とする、請求項12記載の製剤。
- 疾患が、2型糖尿病、単一遺伝子糖尿病、一過性新生児高血糖症、神経心理学的、筋肉又は神経学的障害、及び眼科疾患からなる群において選択されることを特徴とする、請求項11〜13のいずれか一項記載の製剤。
- 単一遺伝子糖尿病が、新生児糖尿病、新生児糖尿病のものと同じ分子機構に含む若年性糖尿病、難聴に関連付けられるミトコンドリア糖尿病(MIDD)、及びMODY糖尿病からなる群において選択されることを特徴とする、請求項14記載の製剤。
- 疾患が、2型糖尿病、新生児糖尿病、及び一過性新生児高血糖症からなる群において選択されることを特徴とする、請求項11〜15のいずれか一項記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1251795 | 2012-02-28 | ||
FR1251795A FR2987268B1 (fr) | 2012-02-28 | 2012-02-28 | Formulations liquides de sulfamides hypoglycemiants |
PCT/FR2013/050421 WO2013128131A1 (fr) | 2012-02-28 | 2013-02-28 | Formulations liquides de sulfamides hypoglycémiants |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015508807A JP2015508807A (ja) | 2015-03-23 |
JP6125542B2 true JP6125542B2 (ja) | 2017-05-10 |
Family
ID=47997565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014559281A Active JP6125542B2 (ja) | 2012-02-28 | 2013-02-28 | 低血糖スルホンアミドの液体製剤 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11110059B2 (ja) |
EP (1) | EP2819679B1 (ja) |
JP (1) | JP6125542B2 (ja) |
AU (1) | AU2013224796C1 (ja) |
CA (1) | CA2863180C (ja) |
DK (1) | DK2819679T3 (ja) |
ES (1) | ES2681495T3 (ja) |
FR (1) | FR2987268B1 (ja) |
IL (1) | IL233939B (ja) |
NZ (1) | NZ627991A (ja) |
PL (1) | PL2819679T3 (ja) |
PT (1) | PT2819679T (ja) |
SI (1) | SI2819679T1 (ja) |
TR (1) | TR201810663T4 (ja) |
WO (1) | WO2013128131A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2987268B1 (fr) | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
CN113648421A (zh) * | 2021-08-19 | 2021-11-16 | 中山大学中山眼科中心 | 磺酰脲类药物在制备治疗葡萄膜炎的药物中的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4313765A (en) * | 1980-09-24 | 1982-02-02 | Merck & Co., Inc. | Synergistic blends of cellulase-free xanthan gum and cellulosics |
DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
EP1117384A1 (en) | 1998-10-01 | 2001-07-25 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
YU8803A (sh) * | 2000-08-07 | 2006-01-16 | Ranbaxy Signature L.L.C. | Tečni oblik metformina |
NZ529544A (en) | 2001-05-31 | 2006-11-30 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
CA2466036C (en) | 2001-10-22 | 2012-04-24 | Taro Pharmaceutical Industries Ltd. | Taste masking spill-resistant formulation |
WO2003097083A1 (fr) * | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Compositions medicinales contenant de la ghreline |
DE102005011786A1 (de) | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
FR2896157B1 (fr) | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
EP1884244A1 (en) * | 2006-08-02 | 2008-02-06 | Assistance Publique - Hopitaux de Paris | Potassium channel ligands for treating diabetes and neuropsychological dysfunction |
JP5235358B2 (ja) | 2007-08-24 | 2013-07-10 | ロート製薬株式会社 | レボカバスチンとリドカインを含有する水性医薬組成物 |
KR20100052262A (ko) * | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물 |
EP2305239A1 (fr) * | 2009-09-24 | 2011-04-06 | Assistance Publique, Hopitaux De Paris | Neuroprotection retinienne par des inhibiteurs des canaux ioniques regules par la sous-unite SUR |
WO2011107855A2 (en) * | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
EP2462922A1 (en) * | 2010-12-10 | 2012-06-13 | Bioprojet | New form of administration of enkephalinase inhibitor |
FR2987268B1 (fr) | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
-
2012
- 2012-02-28 FR FR1251795A patent/FR2987268B1/fr active Active
-
2013
- 2013-02-28 EP EP13712305.5A patent/EP2819679B1/fr active Active
- 2013-02-28 TR TR2018/10663T patent/TR201810663T4/tr unknown
- 2013-02-28 US US14/380,080 patent/US11110059B2/en active Active
- 2013-02-28 AU AU2013224796A patent/AU2013224796C1/en active Active
- 2013-02-28 WO PCT/FR2013/050421 patent/WO2013128131A1/fr active Application Filing
- 2013-02-28 DK DK13712305.5T patent/DK2819679T3/en active
- 2013-02-28 JP JP2014559281A patent/JP6125542B2/ja active Active
- 2013-02-28 PT PT137123055T patent/PT2819679T/pt unknown
- 2013-02-28 CA CA2863180A patent/CA2863180C/fr active Active
- 2013-02-28 PL PL13712305T patent/PL2819679T3/pl unknown
- 2013-02-28 NZ NZ627991A patent/NZ627991A/en unknown
- 2013-02-28 ES ES13712305.5T patent/ES2681495T3/es active Active
- 2013-02-28 SI SI201331109T patent/SI2819679T1/sl unknown
-
2014
- 2014-08-04 IL IL233939A patent/IL233939B/en active IP Right Grant
-
2021
- 2021-08-26 US US17/412,305 patent/US11911505B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2681495T3 (es) | 2018-09-13 |
TR201810663T4 (tr) | 2018-08-27 |
IL233939B (en) | 2019-03-31 |
PT2819679T (pt) | 2018-07-17 |
WO2013128131A1 (fr) | 2013-09-06 |
FR2987268B1 (fr) | 2014-07-11 |
JP2015508807A (ja) | 2015-03-23 |
EP2819679B1 (fr) | 2018-05-16 |
FR2987268A1 (fr) | 2013-08-30 |
SI2819679T1 (sl) | 2019-01-31 |
US11110059B2 (en) | 2021-09-07 |
CA2863180C (fr) | 2020-03-24 |
AU2013224796B2 (en) | 2017-06-29 |
AU2013224796C1 (en) | 2017-12-21 |
US11911505B2 (en) | 2024-02-27 |
IL233939A0 (en) | 2014-09-30 |
EP2819679A1 (fr) | 2015-01-07 |
NZ627991A (en) | 2016-03-31 |
CA2863180A1 (fr) | 2013-09-06 |
US20150051289A1 (en) | 2015-02-19 |
DK2819679T3 (en) | 2018-08-06 |
AU2013224796A1 (en) | 2014-09-18 |
US20210378956A1 (en) | 2021-12-09 |
PL2819679T3 (pl) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2678320B1 (en) | Flumazenil complexes, compositions comprising same and uses thereof | |
CA2703971C (en) | Stabilized pediatric suspension of carisbamate | |
US20170065567A1 (en) | Pharmaceutical Suspension Composition | |
US11911505B2 (en) | Liquid formulations of hypoglycaemic sulfonamides | |
TWI336622B (en) | Water-soluble meloxicam granules | |
CA2829107A1 (en) | A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide | |
US11779566B2 (en) | ST-246 (tecovirimat monohydrate) suspension formulations | |
US20210244657A1 (en) | Edaravone pharmaceutical composition | |
KR20160129887A (ko) | 그라피프란트의 조성물 및 이를 사용하기 위한 방법 | |
CN111741745B (zh) | 多用托拉塞米组合物 | |
CA2660283C (en) | 2-acylaminothiazole compositions and methods for increasing blood platlelet levels in humans | |
JP2019505587A (ja) | ベタメタゾン経口スプレー製剤及び運動失調の治療への使用方法 | |
CA2542755A1 (en) | Biguanide drug-containing jelly preparation | |
US20200306260A1 (en) | Compositions of midazolam for buccal administration in the treatment of seizures to obtain rapid onset of action | |
CN102264344A (zh) | 递送有效浓度的活性剂至眼睛后段的局部眼用溶液组合物 | |
JP2023508085A (ja) | イブプロフェンおよびフェニレフリンを含んでなる液体組成物 | |
CN114760990A (zh) | 钾通道开放剂埃佐加滨的儿科即释制剂 | |
JP2021169431A (ja) | エピナスチン又はその塩を含有する水性組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150312 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160203 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170314 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170405 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6125542 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |